MOF‐818 Nanozyme Suppresses Calcium Oxalate Kidney Stones by Alleviating Oxidative Stress and Inflammatory Injury
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202401574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Yuan Tian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Urological Diseases, Guangdong Engineering Research Center of Urinary Minimally invasive surgery Robot and Int…. Hauptthemen laut MEDLINE: Oxidative Stress, Calcium Oxalate, Kidney Calculi, Inflammation. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
There remains a lack of effective drugs to alleviate the kidney stones caused by oxidative stress and inflammatory damage. The MOF‐818 nanozyme is utilized to lessen the generation of reactive oxygen species (ROS) effectively, restore the membrane potential of mitochondria, regulate the cell cycle, decrease cell death, hinder the recruitment of macrophages, and mitigate the release of inflammatory factors in macrophages. These effects are attributed to the nanozyme's ability to mimic the enzyme properties of catalase (CAT) and superoxide dismutase (SOD). It is demonstrated that this nanozyme can reduce kidney calcium oxalate crystal deposition by reducing the renal injury caused by high concentration oxalate, upregulate the expression levels of SOD and CAT in tissues, downregulate adhesion proteins and inflammatory factor IL‐6 and TNF‐α, and promote the polarization of macrophages from M1 to M2 phenotype in the rat model induced by ethylene glycol. Overall, MOF‐818 has the potential to effectively suppress oxidative stress and inflammatory harm caused by high levels of oxalate, hence lowering the likelihood of stone formation. MOF‐818 nanozyme is also expected to be used as an alternative drug for the treatment of calcium oxalate kidney stones and provide an experimental theoretical basis for the development of new nanomedicines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Urological Diseases, Guangdong Engineering Research Center of Urinary Minimally invasive surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliat…
- Beijing Key Laboratory of Materials Utilization of Nonmetallic Minerals and Solid Wastes, National Laboratory of Mineral Materials, School of Materials Science and Technology, China University of Geosciences, Beijing, 1…
ORCID-Profile: Hongxing Liu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program
- Guangdong Basic and Applied Basic Research Foundation
- Science and Technology Plan Project of Guangzhou
- Guangzhou Medical University Scientific Research Capacity Improvement Program
- National Key Research and Development Program of China
Zitieren
APA
Tian, Y., Ye, Z., Wang, X., Guan, H., Liu, W., Duan, X., Liu, Y., Zeng, G., & Liu, H. (2025). MOF‐818 Nanozyme Suppresses Calcium Oxalate Kidney Stones by Alleviating Oxidative Stress and Inflammatory Injury. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401574
Vancouver
Tian Y, Ye Z, Wang X, Guan H, Liu W, Duan X, et al. MOF‐818 Nanozyme Suppresses Calcium Oxalate Kidney Stones by Alleviating Oxidative Stress and Inflammatory Injury. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202401574
BibTeX
@article{Tian2025,
author = {Tian, Yuan and Ye, Ziyu and Wang, Xunrui and Guan, Hantian and Liu, Weifeng and Duan, Xiaolu and Liu, Yang and Zeng, Guohua and Liu, Hongxing},
title = {MOF‐818 Nanozyme Suppresses Calcium Oxalate Kidney Stones by Alleviating Oxidative Stress and Inflammatory Injury},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202401574}
}
EUVIMED